# Bellicum Pharmaceuticals

Source: https://onco.cc/companies/bellicum/  
OnCo record `bellicum` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bellicum was a Houston cell-therapy company known for its rimiducid safety switch, which let doctors switch off infused T cells; its lead product for transplant failed to reach approval and the company wound down.

## Summary

Bellicum Pharmaceuticals, founded in 2004 in Houston, built cell therapies around an inducible caspase-9 safety switch triggered by the small molecule rimiducid. Its lead product rivogenlecleucel (BPX-501), donor T cells given after haploidentical stem cell transplant in children, reached phase 3 in Europe, and later GoCAR-T products entered early trials before the company ceased operations in 2023. Its trials remain on ClinicalTrials.gov under Bellicum as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Bellicum Pharmaceuticals, Inc.; Bellicum
- Tags: ctgov-sponsor
- HQ: Houston, TX
- Type: cell-therapy
- Website: http://www.bellicum.com

## Sources

- Official website: http://www.bellicum.com
- ClinicalTrials.gov: trials led by Bellicum Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Bellicum%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30257112

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/bellicum.json